Page 1

September 9 , 2026 KANE BIOTECH Kane Biotech to Host Commercial Update Webcast on September 16 Board Chair Philip Renaud , leading wound - care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress , clinical relevance and operational priorities -- Kane Biotech Inc. ( TSX- WINNIPEG , Manitoba , Sept. 09 , 2026 ( GLOBE NEWSWIRE ) V : KNE ) ( the “ Company ” , “ Kane ” or “ Kane Biotech " ) , a biotechnology company commercializing and developing technologies and products that address microbial biofilms , today announced that it will host a virtual Commercial Update on Wednesday , September 16 , 2026 , at 11:00 a.m. Eastern Time . The one - hour webcast will provide shareholders , prospective investors and other stakeholders with an update on Kane's focus on building a clinically credible and commercially disciplined wound - care business , including the Company's strategy to convert revyveⓇ into meaningful , recurring revenue through sustained clinical adoption , productive commercial channels and repeatable product sales . The details of the Webcast are as follows : Date : Wednesday , September 16 , 2026 Time : 11:00 a.m. Eastern Time Duration : Approximately 60 minutes , including a question - and - answer session Format : Virtual presentation followed by a question - and - answer session Registration : Link to Registration Site Investors , shareholders and other stakeholders are encouraged to register in advance to participate in the live webcast and Q & A session . A replay of the webcast will be made available at www.kanebiotech.com following the event .